Last reviewed · How we verify
Ro-Actemra
Ro-Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses.
Ro-Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses. Used for Rheumatoid arthritis, Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.
At a glance
| Generic name | Ro-Actemra |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | IL-6 receptor antagonist |
| Target | IL-6R (Interleukin-6 receptor) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Tocilizumab binds to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signal transduction. This suppresses the production of inflammatory cytokines and acute phase reactants, reducing systemic inflammation in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Giant cell arteritis
- Polyarticular juvenile idiopathic arthritis
- Systemic sclerosis-associated interstitial lung disease
- COVID-19 (severe or critical)
Common side effects
- Infection (including serious infections)
- Elevated liver enzymes
- Hyperlipidemia
- Neutropenia
- Headache
- Hypertension
Key clinical trials
- Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (PHASE2)
- A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action (PHASE4)
- Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis (PHASE3)
- Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ro-Actemra CI brief — competitive landscape report
- Ro-Actemra updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI